Your browser is no longer supported. Please, upgrade your browser.
Settings
IGMS IGM Biosciences, Inc. daily Stock Chart
IGMS [NASD]
IGM Biosciences, Inc.
Index- P/E- EPS (ttm)-1.73 Insider Own1.60% Shs Outstand30.49M Perf Week10.94%
Market Cap1.95B Forward P/E- EPS next Y-3.17 Insider Trans4.19% Shs Float13.38M Perf Month10.90%
Income-52.80M PEG- EPS next Q-0.64 Inst Own55.90% Short Float4.92% Perf Quarter20.38%
Sales- P/S- EPS this Y-80.00% Inst Trans5.47% Short Ratio6.47 Perf Half Y202.27%
Book/sh7.35 P/B8.53 EPS next Y-18.50% ROA-25.70% Target Price61.33 Perf Year-
Cash/sh6.66 P/C9.41 EPS next 5Y- ROE-33.10% 52W Range16.10 - 74.13 Perf YTD64.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-15.47% Beta-
Dividend %- Quick Ratio28.20 Sales past 5Y- Gross Margin- 52W Low289.19% ATR5.41
Employees77 Current Ratio28.20 Sales Q/Q- Oper. Margin- RSI (14)60.14 Volatility9.75% 10.19%
OptionableNo Debt/Eq0.00 EPS Q/Q-7.30% Profit Margin- Rel Volume1.43 Prev Close62.66
ShortableYes LT Debt/Eq0.00 EarningsMar 26 AMC Payout- Avg Volume101.79K Price62.66
Recom1.20 SMA209.98% SMA5015.13% SMA20062.06% Volume0 Change0.00%
Apr-22-20Initiated Wedbush Outperform $73
Oct-14-19Initiated Stifel Buy $32
Oct-14-19Initiated Piper Jaffray Overweight $26
Oct-14-19Initiated Jefferies Buy $25
Oct-14-19Initiated Guggenheim Buy $30
May-12-20 07:00AM  IGM Biosciences to Present at the 2020 RBC Capital Markets Global Healthcare Conference GlobeNewswire -8.33%
May-07-20 04:03PM  IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +5.54%
12:25PM  Was The Smart Money Right About IGM Biosciences, Inc. (IGMS)? Insider Monkey
Apr-29-20 04:05PM  Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19 GlobeNewswire
Apr-03-20 07:00AM  IGM Biosciences to Participate in Canaccord Genuity Horizons in Oncology Virtual Event GlobeNewswire
Mar-26-20 04:05PM  IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire -9.11%
02:30PM  IGM Biosciences Inc to Host Earnings Call ACCESSWIRE
Mar-19-20 07:00AM  IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020 GlobeNewswire +26.59%
Mar-04-20 07:00AM  IGM Biosciences to Present at Two Upcoming Investor Conferences GlobeNewswire +16.14%
Feb-06-20 07:00AM  IGM Biosciences to Present at Two Upcoming Investor Conferences GlobeNewswire
Jan-07-20 07:00AM  IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis GlobeNewswire
Dec-22-19 01:29PM  Hedge Funds Have Never Been This Bullish On IGM Biosciences, Inc. (IGMS) Insider Monkey
Nov-12-19 07:00AM  IGM Biosciences to Present at Three Upcoming Investor Conferences GlobeNewswire
Nov-07-19 05:04PM  IGM Biosciences Announces Third Quarter 2019 Financial Results GlobeNewswire
Nov-01-19 10:24AM  3 Strong Buy Stocks Jefferies Thinks Are Set to Rip Higher TipRanks
Oct-02-19 07:00AM  IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkins Lymphoma GlobeNewswire
Sep-20-19 04:05PM  IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Sep-18-19 11:03AM  IGM Biosciences Opens Above IPO Price Benzinga
07:39AM  The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts Benzinga
Sep-17-19 08:46PM  IGM Biosciences Announces Pricing of Initial Public Offering GlobeNewswire
04:04PM  IGM Biosciences IPO: What You Need To Know Benzinga
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEHRENS M KATHLEENDirectorDec 09Buy24.8720,000497,31610,000Dec 11 07:04 PM